EU Committee Endorses Broader Age Range for AstraZeneca's H5N1 Flu Vaccine
The European Medicines Agency's CHMP has recommended removing the upper age limit for AstraZeneca's intranasal H5N1 pandemic influenza vaccine, potentially extending use from children and adolescents to adults. The vaccine has had conditional EU authorization since May 2016 but is not approved by the FDA or regulators in Asia or South America. Its approval relies on adult immunogenicity studies and phase 3 pediatric efficacy data from a seasonal live attenuated vaccine platform, as no phase 3 trial has tested the H5N1 vaccine itself.
The European Medicines Agency’s CHMP has recommended widening the age range for AstraZeneca’s intranasal H5N1 pandemic influenza vaccine. The change would extend eligibility beyond children and adolescents aged 12 months to younger than 18 years to include adults.
The vaccine has had conditional EU authorization since May 2016. It is not licensed by the FDA or regulators in Asia or South America. Since no phase 3 trial has tested the H5N1 vaccine itself, its approval relies on adult immunogenicity studies and phase 3 pediatric efficacy data from a seasonal live attenuated vaccine platform.
If EU regulators follow the committee’s advice, adults in Europe may gain another option for pandemic H5N1 preparedness, while children and adolescents remain covered. Because the vaccine’s H5N1-specific phase 3 evidence is absent, clinicians and the public could weigh its availability against uncertainty about direct efficacy. Outside Europe, people in regions where the product is not licensed may see less immediate access, though global pandemic planning might still benefit from broader EU use data.